Back to Search Start Over

Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

Source :
Plus Company Updates. February 14, 2018
Publication Year :
2018

Abstract

Germany: Pieris Pharmaceuticals, Inc. has issued the following press release: Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(r) technology platform for cancer, [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Plus Company Updates
Publication Type :
News
Accession number :
edsgcl.527500415